Hi Mate, my take on that phase 1 2 trial is The longer survival was seen in the higher dose (however the low dose survival is still pretty solid). so the entire 240 odd patients haven't been given the higher doses of 2 x 2. obviously with the high dose comes the increased toxicity which is the worry with that drug. but it will come to light shortly.
extract from 2019 the paper states the below.
'Overall survival for the entire treated population was 23.6 months (95% CI, 15.0-32.2) and was significantly longer in the higher-dose cohorts, including a median OS of 42.3 months (range, 19.9-64.7) in the 45 mCi/m2 ×2 cohort (Fig. 2, Table 3).'
Hi Mate, my take on that phase 1 2 trial is The longer survival...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.52 |
Change
0.130(5.44%) |
Mkt cap ! $810.1M | |||
| Open | High | Low | Value | Volume |
| $2.39 | $2.54 | $2.37 | $5.141M | 2.072M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6820 | $2.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.52 | 3500 | 1 |
View Market Depth
| Last trade - 16.17pm 27/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |